Keros Therapeutics Approves $5 Million Share Buyback

MT newswire2026/09/08 20:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

04:21 PM EDT, 09/08/2026 (MT Newswires) -- Keros Therapeutics' (KROS) board approved a $5 million share repurchase program following receipt of a $20 million development milestone payment under its elritercept license agreement with Takeda Pharmaceuticals, the company said Tuesday. The milestone was triggered by dosing of the first patient in the ELRiSE MDS clinical trial, the company said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Keros Therapeutics Approves $5 Million Share Buyback

You may also like

Crypto prices